ZINNAT Film-coated tablet

Active ingredients: Cefuroxime

Product name and form

Zinnat 125 mg film-coated tablets.

Pharmaceutical Form

Film-coated tablet (tablet).

Qualitative and quantitative composition

Each tablet contains 125 mg cefuroxime (as cefuroxime axetil).

Excipient(s) with known effect:

Each tablet contains 0.00152 mg sodium benzoate (E211)

Each tablet contains Methyl parahydroxybenzoate (E218) and Propyl parahydroxybenzoate (E216)

For the full list of excipients, see section 6.1.

Active Ingredient

Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.

List of Excipients

Microcrystalline cellulose
Sodium Laurilsulfate
Croscarmellose Sodium
Hydrogenated vegetable oil
Silica Colloidal Anhydrous
Propylene glycol
Methyl parahydroxybenzoate (E218)
Propyl parahydroxybenzoate (E216)
Opaspray white M-1-7120J [containing titanium dioxide (E171) and sodium benzoate (E211)]

Pack sizes and marketing

Aluminium foil blister pack with an aluminium lid.

Pack size: 6, 10, 12, 14, 16, 20, 24 and 50

Not all pack sizes may be marketed.

Marketing authorization holder

Glaxo Wellcome UK Limited trading as GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex, UB11 1BT

Marketing authorization dates and numbers

PL 10949/0095

15 October 1998


Austria, Australia, Brazil, Cyprus, Ecuador, Estonia, Spain, France, Hong Kong, Ireland, Italy, Lithuania, Netherlands, New Zealand, Poland, Singapore, Tunisia, United Kingdom, South Africa